RUNX1 and acute myeloid leukemia: However, when the authors incorporated concurrent expression of a mutant form of RUNX1 into their mouse model, they found that co-expression of these two mutations led to development of frank MDS/AML with a short latency period following induced expression of the mutations (median survival of 160 days).